Back to News
Market Impact: 0.48
Intellia's Lonvo-z BLA Gets FDA Priority Review For Hereditary Angioedema; PDUFA Set For March 2027
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Intellia Therapeutics said the FDA accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z) to treat hereditary angioedema and granted the therapy Priority Review. The expedited review is a meaningful regulatory milestone that could accelerate a potential commercial launch and is likely positive for NTLA shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
NTLA0.85
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- Piero Cipollone: Interview with Milano Finanza